



Spectrum Pharmaceuticals Highlights Data Showing Pozitotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago

April 17, 2018

HENDERSON, Nev.--(BUSINESS WIRE)--Apr. 17, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced a poster presentation of data from preclinical and clinical studies evaluating pozitotinib in HER2 exon 20 mutations in non-small cell lung cancer (NSCLC) and summarizing a dataset of the prevalence of HER2 exon 20 across solid tumors by scientists from the University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) which is taking place in Chicago, Illinois, April 14-18, 2018.

"We are excited to see the first presentation of data for pozitotinib in HER2 exon 20 mutations in NSCLC," said Joe Turgeon, President and Chief Executive Officer of Spectrum Pharmaceuticals. "These data build upon previous results from pozitotinib studies and indicate that this drug could be effective in treating both EGFR and HER2 exon 20 mutations. Furthermore, new data from MD Anderson reveal that these mutations are found across a variety of solid tumors and there is strong rationale for evaluating pozitotinib in a basket study."

"The pre-clinical and early clinical activity of pozitotinib in EGFR and HER2 exon 20 mutant NSCLC suggests pozitotinib could be a promising agent for the numerous cancer types driven by HER2 exon 20 mutations," said Jacquelyne Robichaux, Ph.D, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center. "We have previously shown that pozitotinib is an effective inhibitor of EGFR exon 20 insertion mutations in vitro and in vivo. These data show that pozitotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers. Further evaluation of pozitotinib in solid tumors is warranted."

About Pozitotinib

Pozitotinib is a novel, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4. Importantly this, in turn, leads to the inhibition of the proliferation of tumor cells that overexpress these receptors. Mutations or overexpression/amplification of EGFR family receptors have been associated with a number of different cancers, including non-small cell lung cancer (NSCLC), breast cancer, and gastric cancer. Spectrum received exclusive license to develop, manufacture, and commercialize worldwide excluding Korea and China from Hanmi Pharmaceuticals. Pozitotinib is currently being investigated by Spectrum and Hanmi in several mid-stage trials in multiple solid tumor indications.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology Company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the Company. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.

Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum's business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum's existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2018 Spectrum Pharmaceuticals, Inc. All Rights Reserved

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180417006420/en/>

Source: Spectrum Pharmaceuticals

Spectrum Pharmaceuticals
Shiv Kapoor
Vice President, Strategic Planning & Investor Relations
702-835-6300
InvestorRelations@sppirx.com